BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29962332)

  • 21. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics.
    Lorenzer C; Dirin M; Winkler AM; Baumann V; Winkler J
    J Control Release; 2015 Apr; 203():1-15. PubMed ID: 25660205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy.
    Dong Y; Yu T; Ding L; Laurini E; Huang Y; Zhang M; Weng Y; Lin S; Chen P; Marson D; Jiang Y; Giorgio S; Pricl S; Liu X; Rocchi P; Peng L
    J Am Chem Soc; 2018 Nov; 140(47):16264-16274. PubMed ID: 30346764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide-based targeted polymeric nanoparticles for siRNA delivery.
    Hussein WM; Cheong YS; Liu C; Liu G; Begum AA; Attallah MA; Moyle PM; Torchilin VP; Smith R; Toth I
    Nanotechnology; 2019 Oct; 30(41):415604. PubMed ID: 31295734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances of siRNA delivery by nanoparticles.
    Yuan X; Naguib S; Wu Z
    Expert Opin Drug Deliv; 2011 Apr; 8(4):521-36. PubMed ID: 21413903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review.
    Varshosaz J; Taymouri S
    Curr Pharm Des; 2015; 21(29):4310-28. PubMed ID: 26323421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
    Sivakumar P; Kim S; Kang HC; Shim MS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Liposomes for siRNA Delivery to Cancer.
    Eloy JO; Petrilli R; Raspantini GL; Lee RJ
    Curr Pharm Des; 2018; 24(23):2664-2672. PubMed ID: 30084323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing the Delivery of Chemotherapeutics: Role of Biodegradable Polymeric Nanoparticles.
    Ahlawat J; Henriquez G; Narayan M
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30150595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
    Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
    Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
    Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
    Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient siRNA delivery with non-viral polymeric vehicles.
    Kim WJ; Kim SW
    Pharm Res; 2009 Mar; 26(3):657-66. PubMed ID: 19015957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
    Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
    Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent progress in development of siRNA delivery vehicles for cancer therapy.
    Kim HJ; Kim A; Miyata K; Kataoka K
    Adv Drug Deliv Rev; 2016 Sep; 104():61-77. PubMed ID: 27352638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymers in the Delivery of siRNA for the Treatment of Virus Infections.
    Reynolds N; Dearnley M; Hinton TM
    Top Curr Chem (Cham); 2017 Apr; 375(2):38. PubMed ID: 28324594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
    Joo MK; Yhee JY; Kim SH; Kim K
    J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers.
    Sun H; Yarovoy I; Capeling M; Cheng C
    Top Curr Chem (Cham); 2017 Apr; 375(2):24. PubMed ID: 28176270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.
    Elzeny H; Zhang F; Ali EN; Fathi HA; Zhang S; Li R; El-Mokhtar MA; Hamad MA; Wooley KL; Elsabahy M
    Drug Des Devel Ther; 2017; 11():483-496. PubMed ID: 28260861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.